Design, Synthesis, Computational, and Preclinical Evaluation of natTi/45Ti-Labeled Urea-Based Glutamate PSMA Ligand

Synthesis and stability of the [45Ti]Ti-DOTA complex: en route towards aza-macrocyclic 45Ti-based radiopharmaceuticals

We report the use of DOTA as a chelator for titanium. The resulting complex is fully characterised and in vitro stability studies reveal its high kinetic inertness against transmetallation and transchelation. The radiolabeling of DOTA with 45Ti, via a guaiacol-based liquid-liquid extraction method, leads to a high radiochemical conversion up to 98%.

Novel Titanocene Y derivative with albumin affinity exhibits improved anticancer activity against platinum resistant cells

The antitumor activity of Ti(IV)-based compounds put them in the spotlight for cancer treatment in the past, but their lack of stability in vivo due to a high rate of hydrolysis has hindered their development as antitumor drugs. As a possible solution for this problem, we have reported a synthesis strategy through which we combined a titanocene fragment, a tridentate ligand, and a long aliphatic chain. This strategy allowed us to generate a titanium compound (Myr-Ti) capable of interacting with albumin, highly stable in water and with cytotoxic activity in tumor cells[1]. Following a similar strategy, now we report the synthesis of a new compound (Myr-TiY) derived from titanocene Y that shows antitumoral activity in a cisplatin resistant model with a 50% inhibitory concentration (IC50) of 41-76 μM. This new compound shows high stability and a strong interaction with human serum albumin. Myr-TiY has a significant antiproliferative and proapoptotic effect on the tested cancer cells and shows potential tumor selectivity when assayed in non-tumor human epithelial cells being more selective (1.3-3.8 times) for tumor cells than cisplatin. These results lead us to think that the described synthesis strategy could be useful to generate compounds for the treatment of both cisplatin-sensitive and cisplatin-resistant cancers.

"Off-Label Use" of the Siderophore Enterobactin Enables Targeted Imaging of Cancer with Radioactive Ti(IV)

The development of inert, biocompatible chelation methods is required to harness the emerging positron emitting radionuclide 45Ti for radiopharmaceutical applications. Herein, we evaluate the Ti(IV)-coordination chemistry of four catechol-based, hexacoordinate chelators using synthetic, structural, computational, and radiochemical approaches. The siderophore enterobactin (Ent) and its synthetic mimic TREN-CAM readily form mononuclear Ti(IV) species in aqueous solution at neutral pH. Radiolabeling studies reveal that Ent and TREN-CAM form mononuclear complexes with the short-lived, positron-emitting radionuclide 45Ti(IV), and do not transchelate to plasma proteins in vitro and exhibit rapid renal clearance in naïve mice. These features guide efforts to target the 45Ti isotope to prostate cancer tissue through the design, synthesis, and evaluation of Ent-DUPA, a small molecule conjugate composed of a prostate specific membrane antigen (PSMA) targeting peptide and a monofunctionalized Ent scaffold. The [45Ti][Ti(Ent-DUPA)]2- complex forms readily at room temperature. In a tumor xenograft model in mice, selective tumor tissue accumulation (8±5 %, n=5), and low off-target uptake in other organs is observed. Overall, this work demonstrates targeted imaging with 45Ti(IV), provides a foundation for advancing the application of 45Ti in nuclear medicine, and reveals that Ent can be repurposed as a 45Ti-complexing cargo for targeted nuclear imaging applications.

Titanium-45 (45Ti) Radiochemistry and Applications in Molecular Imaging

Molecular imaging is an important part of modern medicine which enables the non-invasive identification and characterization of diseases. With the advancement of radiochemistry and scanner technology, nuclear medicine is providing insight into efficient treatment options for individual patients. Titanium-45 (45Ti) is a lesser-explored radionuclide that is garnering increasing interest for the development of positron emission tomography (PET) radiopharmaceuticals. This review discusses aspects of this radionuclide including production, purification, radiochemistry development, and molecular imaging studies.

Radiochemistry and In Vivo Imaging of [45Ti]Ti-THP-PSMA

Titanium-45 (45Ti) is a radionuclide with excellent physical characteristics for use in positron emission tomography (PET) imaging, including a moderate half-life (3.08 h), decay by positron emission (85%), and a low mean positron energy of 0.439 MeV. However, challenges associated with titanium chemistry have led to the underdevelopment of this radionuclide for incorporation into radiopharmaceuticals. Expanding on our recent studies, which showed promising results for the complexation of 45Ti with the tris hydroxypyridinone (THPMe) chelator, the current work aimed to optimize the chemistry and imaging attributes of [45Ti]Ti-THP-PSMA as a new PET radiopharmaceutical. Methods. Radiolabeling of THP-PSMA was optimized with [45Ti]Ti-citrate at varying pHs and masses of the precursor. The stability of the radiolabeled complex was assessed in mouse serum for up to 6 h. The affinity of [45Ti]Ti-THP-PSMA for prostate-specific membrane antigen (PSMA) was assessed using LNCaP (PSMA +) and PC3 (PSMA -) cell lines. In vivo imaging and biodistribution analysis were performed in tumor-bearing xenograft mouse models to confirm the specificity of the tumor uptake. Results. > 95% of radiolabeling was achieved with a high specific activity of 5.6 MBq/nmol under mild conditions. In vitro cell binding studies showed significant binding of the radiolabeled complex with the PSMA-expressing LNCaP cell line (11.9 ± 1.5%/mg protein-bound activity) compared to that with the nonexpressing PC3 cells (1.9 ± 0.4%/mg protein-bound activity). In vivo imaging and biodistribution studies confirmed specific uptake in LNCaP tumors (1.6 ± 0.27% ID/g) compared to that in PC3 tumors (0.39 ± 0.2% ID/g). Conclusion. This study showed a simple one-step radiolabeling method for 45Ti with THP-PSMA under mild conditions (pH 8 and 37 °C). In vitro cell studies showed promise, but in vivo tumor xenograft studies indicated low tumor uptake. Overall, this study shows the need for more chelators for 45Ti for the development of a PET radiopharmaceutical for cancer imaging.

"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617

BACKGROUND

Prostate-specific membrane antigen (PSMA) is an ideal target for molecular imaging and targeted radionuclide therapy in prostate cancer. Consequently, various PSMA ligands were developed. Some of these molecules are functionalized with a chelator that can host radiometals, such as 68Ga for PET imaging. The 68Ga radiolabeling step benefits from process automation, making it more robust and reducing radiation exposure.

OBJECTIVE

To design a single automated radiolabeling protocol for the GMP-compliant preparation of [68Ga]Ga-PSMA-11, transposable to the production of [68Ga]Ga-PSMA-617 and [68Ga]Ga-PSMA-I&T.

METHODS

A GAIA® synthesis module and a GALLIAD® generator were used. Radio-TLC and radio-HPLC methods were validated for radiochemical purity (RCP) determination. Three [68Ga]Ga-PSMA-11 validation batches were produced and thoroughly tested for appearance and pH, radionuclide identity and purity, RCP, stability, residual solvent and sterility. Minimal modifications were made to the reagents and disposables for optimal application to other PSMA ligands.

RESULTS

[68Ga]Ga-PSMA-11 for clinical application was produced in 27 min. The 3 validation batches met the quality criteria expected by the European Pharmacopoeia to allow routine production. For optimal transposition to PSMA-617, the solid phase extraction cartridge was changed to improve purification of the radiolabeled product. For application to PSMA-I&T, the buffer solution initially used was replaced by HEPES 2.7 M to achieve good radiochemical yields. Residual HEPES content was checked in the final product and was below the Ph. Eur. threshold.

CONCLUSION

A single automated radiolabeling method on the GAIA® module was developed and implemented for 68Ga radiolabeling of 3 PSMA ligands, with slight adjustments for each molecule.

Polydentate N,O-Ligands Possessing Unsymmetrical Urea Fragments Attached to a p-Cresol Scaffold

In this study, three series of polydentate N,O-ligands possessing unsymmetrical urea fragments attached to a p-cresol scaffold are obtained, namely mono- and bi-substituted open-chain aromatics, synthesised using a common experiment, as well as fused aryloxazinones. Separate protocols for the preparation of each series are developed. It is found that in the case of open-chain compounds, the reaction output is strongly dependent on both bis-amine and carbamoyl chloride substituents, while oxazinones can be effectively obtained via a common protocol. The products are characterized via 1D and 2D NMR spectra in solution and using single-crystal XRD. A preliminary study on the coordination abilities of the products performed via ITC shows that there are no substantial interactions in the pH range of 5.0-8.5 in general.

Preparation and quality control of a new porphyrin complex labeled with 45Ti for PET imaging

This study aims to produce and quality control of a new porphyrin complex labeled with ⁴⁵Ti for PET imaging, so at the first step, the cross-section of ⁴⁵Sc(p,n)⁴⁵Ti was investigated by TALYS-1.6 and the optimal target thickness and theoretical yield were calculated by SRIM code. The purified ⁴⁵Ti was labeled with the anticancer agent of tetrakis (pentafluorophenyl) porphyrin (TFPP). The radiochemical purity and the percentage of labeling were evaluated by radiation layer chromatography then the division coefficient of [⁴⁵Ti]-TFPP was calculated. The dual coincidence imaging system was used for imaging 1 and 2 h after injection [⁴⁵Ti]-TFPP to rats. Immediately after imaging, the mean percent injected dose per gram and specific activity of different tissues including blood, heart, lungs, stomach, liver, bone, kidney, spleen, intestine, muscle, feces, and skin were measured. The yield of ⁴⁵Ti production was measured 468 MBq/μAh and the labeling rate was observed more than 98%. The highest activity was observed in the liver (%ID/g = 2.27%, 1 h) and spleen (2.2%, 1 h), respectively, because of the high lipophilic of ⁴⁵Ti-TFPP. SPECT images showed a significant uptake of radiopharmaceuticals in the abdomen. The labeling rate of ⁴⁵Ti-TFPP was high and this compound has the potential for clinical application in different ways than PSMA, it can be joined with photodynamic therapy (Severin et al., 2015).

Synthesis and X-ray structure analysis of cytotoxic heptacoordinated Salan hafnium(IV) complexes stabilized with 2,6-dipicolinic acid

Four novel Salan Hf^(IV) complexes stabilized by 2,6-dipicolinic acid (Dipic) were synthesized and characterized by ¹H, ¹³C NMR and X-ray diffraction spectroscopy. These Hf^(IV)bis-chelates could be obtained in good to excellent yields (88%-91%) and demonstrated rather good stability in aqueous media and on silica gel. [L₂Hf^(IV)Dipic^4-H,Cl] containing steric bulk L₂ were stable in about 10% H₂O (H₂O/THF (v/v)), however, [L₁Hf^(IV)Dipic^4-H,Cl] with non-steric L₁ could slowly dissociate and release nontoxic L₁. [L_1-2Hf^(IV)Dipic^4-Cl] showed excellent anti-tumoral activity in the range of cisplatin (Hela S3: IC₅₀ = 3.5 ± 0.4 μM, Hep G2: IC₅₀ = 11.2 ± 2.1 μM). In addition, the cellular uptake and apoptosis investigation of [L₁Hf^(IV)Dipic^4-Cl] suggested a fast cellular uptake process against Hela S3 cells with an almost exclusive induced apoptosis cell death path.

Recovery of Gallium-68 and Zinc from HNO3-Based Solution by Liquid-Liquid Extraction with Arylamino Phosphonates

The cyclotron production of gallium-68 via the ⁶⁸Zn(p,n)⁶⁸Ga nuclear reaction in liquid targets is gaining significant traction in clinics. This work describes (1) the synthesis of new arylamino phosphonates via the Kabachnik-Fields reaction, (2) their use for liquid-liquid extraction of ⁶⁸Ga from 1 M Zn(NO₃)₂/0.01 M HNO₃ in batch and continuous flow, and (3) the use of Raman spectroscopy as a process analytical technology (PAT) tool for in-line measurement of ⁶⁸Zn. The highest extraction efficiencies were obtained with the extractants functionalized with trifluoromethyl substituents and ethylene glycol ponytails, which were able to extract up to 90% of gallium-68 in batch and 80% in flow. Only ppm amounts of zinc were co-extracted. The extraction efficiency was a function of pKa and the aqueous solubility of the extractant and showed marked concentration, solvent, and temperature dependence. Raman spectroscopy was found to be a promising PAT tool for the continuous production of gallium-68.

Facile synthesis of [ONON] type titanium(IV)bis-chelated complexes in alcoholic solvents and evaluation of anti-tumor activity

Novel anti-tumoral diamino-bis-(phenolato) [ONON] type titanium^(IV) complexes stabilized by 2,6-dipicolinic acid were synthesis via an efficient protocol using n-propanol as solvent and H₂O for isolation. In total 20 [ONON] type and 2 Salan Ti^(IV)bis-chelated complexes were synthesized with yields ranging from 68% to 96%. All reactions could reach to completion in 1.5 min at 80 °C either using Ti(OⁱPr)₄ or TiCl₄ as starting materials. Most [ONON] type Ti^(IV) complexes exhibit selectively enhanced inhibition activity against Hep G2 cells in comparison with Salan Ti^(IV) complexes. Among which, the inhibitory activity of 2 t (IC₅₀: 0.15 ± 0.1 μM) against Hep G2 cells is about 80 times enhanced than that of cisplatin (IC₅₀: 12.4 ± 1.2 μM). The [ONON] type Ti^(IV) complexes slowly released nontoxic phenolato ligands in presence of large amount of aqueous media, and a fast cellular uptake process was proposed for these Ti^(IV) complexes based on metal uptake analysis. Decagram scale synthesis indicates this facile synthetic methodology can be applied to large scale synthesis.

A General Design Strategy Enabling the Synthesis of Hydrolysis-Resistant, Water-Stable Titanium(IV) Complexes

Despite its prevalence in the environment, the chemistry of the Ti⁴⁺ ion has long been relegated to organic solutions or hydrolyzed TiO₂ polymorphs. A knowledge gap in stabilizing molecular Ti⁴⁺ species in aqueous environments has prevented the use of this ion for various applications such as radioimaging, design of water-compatible metal-organic frameworks (MOFs), and aqueous-phase catalysis applications. Herein, we show a thorough thermodynamic screening of bidentate chelators with Ti⁴⁺ in aqueous solution, as well as computational and structural analyses of key compounds. In addition, the hexadentate analogues of catechol (benzene-1,2-diol) and deferiprone (3-hydroxy-1,2-dimethyl-4(1H)-pyridone), TREN-CAM and THP^Me respectively, were assessed for chelation of the ⁴⁵ Ti isotope (t_1/2 =3.08 h, β⁺ =85 %, E_β+ =439 keV) towards positron emission tomography (PET) imaging applications. Both were found to have excellent capacity for kit-formulation, and [⁴⁵ Ti]Ti-TREN-CAM was found to have remarkable stability in vivo.

Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors

Prostate-specific membrane antigen (PSMA), also called glutamate carboxypeptidase II (GCP(II)), is a Zn-dependent metalloprotease that is known as a well prostate cancer indication and a potential targeting towards anti-cancer medicines and drug delivery. Because of its centrality in the diagnostics and treatment of prostate cancer, several types of inhibitors are designed with particular scaffolds. In this study, important groups of related inhibitors as well as reported experimental and computational studies are being reviewed, in which we examined three functional groups on each group of structures. The importance of computational biochemistry and the necessity of extensive research in this area on PSMA and its effective ligands are recommended.

The crystal structure of 6,6′-(((2-(dimethylamino)ethyl)azanediyl)bis(methylene))bis(benzo[d][1,3]dioxol-5-ol ato-κ4 N,N′,O,O′)-(pyridine-2,6-dicarboxylato-N,O,O′)-titanium(IV)-dichloromethane(1/1), C27H25N3O10Ti

C27H25N3O10Ti, monoclinic, P21/n (no. 14), a = 11.3366(11) Å, b = 11.0253(11) Å, c = 23.7160(2) Å, β = 100.839(2)°, V = 2911.4(5) Å3, Z = 4, R gt (F) = 0.0615, wR ref (F 2) = 0.1411, T = 296(2) K.

The crystal structure of 1,1′-(((2 (dimethylamino)ethyl)azanediyl)bis(methylene)) bis(naphthalen-2-olato-κ4 N,N′,O,O′)-(pyridine-2,6-dicarboxylato-N,O,O′)- titanium(IV) ─ dichloromethane (2/1), C33H29N3O6Ti

C33H29N3O6Ti, monoclinic, C2/c (no. 15), a = 27.4022(15) Å, b = 14.0345(7) Å, c = 17.0047(10) Å, β = 116.009(3)°, V = 5877.3(6) Å3, Z = 8, R gt (F) = 0.0369, wRref (F 2) = 0.1125, T = 100(2) K.

New titanocene derivative with improved stability and binding ability to albumin exhibits high anticancer activity

Titanium-based therapies have emerged as a promising alternative for the treatment of cancer patients, particularly those with cisplatin resistant tumors. Unfortunately, some titanium compounds show stability and solubility problems that have hindered their use in clinical practice. Here, we designed and synthesized a new titanium complex containing a titanocene fragment, a tridentate ligand to improve its stability in water, and a long aliphatic chain, designed to facilitate a non-covalent interaction with albumin, the most abundant protein in human serum. The stability and human serum albumin affinity of the resulting titanium complex was investigated by UV-Vis absorption and fluorescence spectroscopy techniques. Complex [TiCp₂{(OOC)₂py-O-myr}] (3) (myr = C₁₄H₂₉, py = pyridine) and its analogous [TiCp₂{(OOC)₂py-OH}] (4), lacking the aliphatic chain, showed improved stability in phosphate saline buffer compared with [TiCp₂Cl₂] (1). 3 showed a strong interaction with human serum albumin in a 1:1 stoichiometry. The cytotoxic effect of 3 was higher compared to [TiCp₂Cl₂] in tumor cell lines and showed potential tumor selectivity when assayed in non-tumor human epithelial cells. Finally, 3 showed an antiproliferative effect on cancer cells, decreasing the population in the S phase, and increasing apoptotic cells in a significant manner. All this makes the novel Ti(IV) compound 3 a firm candidate to continue further studies of its therapeutic potential in vitro and in vivo.

Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer

Prostate-specific membrane antigen (PSMA) is a well-established biological target that is overexpressed on the surface of prostate cancer lesions. Radionuclide-labeled small-molecule PSMA inhibitors have been shown to be promising PSMA-specific agents for the diagnosis and therapy of prostate cancer. In this study, a glutamate-urea-based PSMA-targeted ligand containing an isonitrile (CNGU) was synthesized and labeled with ^99mTc to prepare [^99mTc]Tc-CNGU with a high radiochemical purity (RCP). The CNGU ligand showed a high affinity toward PSMA (K_i value is 8.79 nM) in LNCaP cells. The [^99mTc]Tc-CNGU exhibited a good stability in vitro and hydrophilicity (log P = −1.97 ± 0.03). In biodistribution studies, BALB/c nude mice bearing LNCaP xenografts showed that the complex had a high tumor uptake with 4.86 ± 1.19% ID/g, which decreased to 1.74 ± 0.90% ID/g after a pre-injection of the selective PSMA inhibitor ZJ-43, suggesting that it was a PSMA-specific agent. Micro-SPECT imaging demonstrated that the [^99mTc]Tc-CNGU had a tumor uptake and that the uptake was reduced in the image after blocking with ZJ-43, further confirming its PSMA specificity. All of the results in this work indicated that [^99mTc]Tc-CNGU is a promising PSMA-specific tracer for the imaging of prostate cancer.

Thermochromatographic separation of 45Ti and subsequent radiosynthesis of [45Ti]salan

Due to its favorable decay properties, the non-standard radionuclide 45Ti is a promising PET isotope for tumor imaging. Additionally, titanium complexes are widely used as anti-tumor agents and 45Ti could be used to study their in vivo distribution and metabolic fate. However, although 45Ti can be obtained using the 45Sc(p,n)45Ti nuclear reaction its facile production is offset by the high oxophilicity and hydrolytic instability of Ti4+ ions in aqueous solutions, which complicate recovery from the irradiated Sc matrix. Most available 45Ti recovery procedures rely on ion exchange chromatography or solvent extraction techniques which are time-consuming, produce large final elution volumes, or, in case of solvent extraction, cannot easily be automated. Thus a more widespread application of 45Ti for PET imaging has been hampered. Here, we describe a novel, solvent-free approach for recovery of 45Ti that involves formation of [45Ti]TiCl4 by heating of an irradiated Sc target in a gas stream of chlorine, followed by thermochromatographic separation of the volatile radiometal chloride from co-produced scandium chloride and trapping of [45Ti]TiCl4 in a glass vial at − 78 °C. The recovery of 45Ti amounted to 76 ± 5% (n = 5) and the radionuclidic purity was determined to be > 99%. After trapping, the [45Ti]TiCl4 could be directly used for 45Ti-radiolabeling, as demonstrated by the successful radiosynthesis of [45Ti][Ti(2,4-salan)].